Analysis
Apnimed priced an upsized initial public offering at $16.00 per share, the top of its range, raising $192 million ahead of its Nasdaq debut under the ticker APMD. The company sold 12 million shares, 20% more than originally planned, and granted underwriters a 30-day option to purchase up to 1.8 million additional shares. The offering is expected to close around August 3.
Apnimed is developing oral therapies for sleep-related breathing diseases, with its lead Phase 3 candidate positioned as a potential first FDA-approved pill for obstructive sleep apnea -- a market currently dominated by CPAP machines and other mechanical devices that suffer from notoriously poor long-term patient compliance. A pill-based alternative, if approved, would address a genuine unmet need in a large and underserved patient population.
“What to watch: Apnimed's first-day trading performance relative to Scribe's pop, and its Phase 3 data readout timeline.”
The upsized, top-of-range pricing continues a strong run for biotech debuts this month: Scribe Therapeutics priced its own IPO on July 23 and popped nearly 44% on its first trading day, suggesting investor appetite for clinical-stage biotech listings remains healthy even as broader tech IPO sentiment has been more selective.
For biotech-focused investors, Apnimed's reception is a live test of whether the current IPO window rewards single-indication, late-stage clinical assets as reliably as it has rewarded AI-adjacent platform stories this year. The bear case: pharmaceutical approval risk doesn't disappear at IPO, and a Phase 3 miss would erase the premium the company is commanding today regardless of how strong the offering priced. What to watch: Apnimed's first-day trading performance relative to Scribe's pop, and its Phase 3 data readout timeline.
